Drug firm Dr. Reddy’s Labs Ltd said it has launched in the US market levocetirizine dihydrochloride tablets, used for relieving allergies.
In a BSE filing, the labs said it had “launched levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of UCB’s Xyzal allergy tablets, in the US market as approved by the US Food and Drug Administration (USFDA).”
Levocetirizine dihydrochloride tablets are used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose and sneezing.
According IRI sales data, Xyzal allergy tablets had sales of about $71 million in the US market for the 12-month period ended January 2018.
At 1.17pm, Dr. Reddy’s Labs shares were trading at Rs2,160.90 on the BSE, down 1.02%, while the Sensex fell 0.89% to 33,385.84.